Dehydroepiandrosterone production pathway (DHEA pathway)

The Dehydroepiandrosterone (DHEA) production pathway is a multi-step biochemical process responsible for the synthesis of DHEA, the most abundant circulating steroid prohormone in humans (NIH, 2024). This pathway primarily occurs in the zona reticularis of the adrenal cortex, as well as in the gonads and the central nervous system (Wikipedia, 2024). It begins with the conversion of cholesterol to pregnenolone by the mitochondrial enzyme CYP11A1 (P450scc), followed by the sequential 17-alpha-hydroxylation and 17,20-lyase activities of the microsomal enzyme CYP17A1 (StatPearls, 2023). DHEA serves as a critical metabolic intermediate, providing the substrate for the peripheral production of potent androgens and estrogens, which regulate reproductive health, bone density, and mood (MDPI, 2023). Dysregulation of this pathway is central to the pathogenesis of conditions such as castration-resistant prostate cancer, polycystic ovary syndrome (PCOS), and congenital adrenal hyperplasia (PubMed, 2024). Therapeutic strategies often involve the inhibition of key enzymes like CYP17A1 to deprive hormone-dependent tumors of androgens (DrugBank, 2024). Conversely, DHEA supplementation is explored for treating adrenal insufficiency and age-related hormonal decline, although its systemic benefits remain a topic of clinical investigation (NIH, 2024).

Other names

DHEA biosynthesis pathwayDelta-5 steroidogenic pathwayAdrenal androgen biosynthesis pathway

Drugs targeting this pathway primarily inhibit the enzyme Cytochrome P450 17A1 (CYP17A1), which possesses both 17-alpha-hydroxylase and 17,20-lyase activities. Inhibition of the 17,20-lyase activity specifically blocks the conversion of 17-hydroxypregnenolone to DHEA, thereby reducing the production of downstream androgens and estrogens (NIH, 2024). Other agents may inhibit steroid sulfatase (STS) to prevent the conversion of DHEA-S back to active DHEA (PubMed, 2023).